GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (FRA:1UC) » Definitions » EV-to-FCF

Cue Biopharma (FRA:1UC) EV-to-FCF : -1.00 (As of Apr. 03, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Cue Biopharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cue Biopharma's Enterprise Value is €33.79 Mil. Cue Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-33.75 Mil. Therefore, Cue Biopharma's EV-to-FCF for today is -1.00.

The historical rank and industry rank for Cue Biopharma's EV-to-FCF or its related term are showing as below:

FRA:1UC' s EV-to-FCF Range Over the Past 10 Years
Min: -22.7   Med: -3.54   Max: -0.19
Current: -1

During the past 10 years, the highest EV-to-FCF of Cue Biopharma was -0.19. The lowest was -22.70. And the median was -3.54.

FRA:1UC's EV-to-FCF is ranked worse than
100% of 447 companies
in the Biotechnology industry
Industry Median: 2.69 vs FRA:1UC: -1.00

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-03), Cue Biopharma's stock price is €0.685. Cue Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.693. Therefore, Cue Biopharma's PE Ratio (TTM) for today is At Loss.


Cue Biopharma EV-to-FCF Historical Data

The historical data trend for Cue Biopharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cue Biopharma EV-to-FCF Chart

Cue Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.13 -7.80 -1.57 -2.27 -1.52

Cue Biopharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.27 -1.64 -1.08 -0.59 -1.52

Competitive Comparison of Cue Biopharma's EV-to-FCF

For the Biotechnology subindustry, Cue Biopharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cue Biopharma's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cue Biopharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Cue Biopharma's EV-to-FCF falls into.


;
;

Cue Biopharma EV-to-FCF Calculation

Cue Biopharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=33.785/-33.747
=-1.00

Cue Biopharma's current Enterprise Value is €33.79 Mil.
Cue Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-33.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cue Biopharma  (FRA:1UC) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Cue Biopharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.685/-0.693
=At Loss

Cue Biopharma's share price for today is €0.685.
Cue Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.693.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Cue Biopharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Cue Biopharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cue Biopharma Business Description

Traded in Other Exchanges
Address
40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Cue Biopharma Headlines

No Headlines